Assessment and relevance of enzyme-linked immunosorbent assay for antibodies to Saccharomyces cerevisiae in Australian patients with inflammatory bowel disease.
The frequency of antibodies to Saccharomyces cerevisiae (ASCA) in Crohn's disease, ulcerative colitis and non-inflammatory bowel disease controls has been compared using two commercially available assays. The Medizym test resulted in sensitivity of 50% and specificity of 93% for Crohn's disease. The corresponding figures for the QUANTA Lite assay were 79% and 74%, respectively. Using ASCA and perinuclear antineutrophil cytoplasmic antibody (pANCA) in combination, the sensitivity and specificity of ASCA+/pANCA- for Crohn's disease using the Medizym kit were 50% and 100%, respectively, compared with 79% and 93% using QUANTA Lite. ASCA-/pANCA+ was 100% specific for ulcerative colitis with either assay. ASCA can be found in Australian patients with Crohn's disease at a similar frequency to that reported overseas.
Moore
M M
MM
Department of Medicine, University of Sydney, New South Wales, Australia.
Fabricatorian
D
D
Selby
W S
WS
D000328:Adult; D000368:Aged; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000097:blood; D000974:Antibodies, Antinuclear / Q000097:blood*; D003093:Colitis, Ulcerative / Q000175:diagnosis* / Q000382:microbiology; D003424:Crohn Disease / Q000175:diagnosis* / Q000382:microbiology; D003937:Diagnosis, Differential; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D012441:Saccharomyces cerevisiae / Q000276:immunology*; D012680:Sensitivity and Specificity
D019268:Antibodies, Antineutrophil Cytoplasmic; D000974:Antibodies, Antinuclear; D007070:Immunoglobulin A; D007074:Immunoglobulin G